APTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 12月 2023 @ 05:59):

Stats
本日の出来高	231 126
平均出来高	132 918
時価総額	6.50M
EPS	$0 ( 2024-04-04 )
次の収益日	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0980
ATR14	$0.00400 (4.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-03	Khanna Ashish	Buy	375 000	Stock Option (Right to Buy)
2023-01-03	Riedel Norbert G	Buy	420 000	Stock Option (Right to Buy)
2023-01-03	Kidd Andrew	Buy	700 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 16 590 862 \| Sell: 1 518 818

ボリューム相関

長: 0.42 (neutral)

短: 0.45 (neutral)

Signal:(66.425) Neutral

Aptinyx Inc 相関

10 最も正の相関
GNUS	0.981
UEIC	0.973
GMBL	0.966
QNRX	0.946
FAMI	0.945
BAND	0.945
JAGX	0.943
INFI	0.942
PIXY	0.94
GROM	0.938

10 最も負の相関
AGFS	-0.94
APEN	-0.935
LMRK	-0.889
SGEN	-0.885
KNBE	-0.884
TIG	-0.883
MYRG	-0.876
RDUS	-0.875
QADA	-0.871
IMRA	-0.862

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aptinyx Inc 相関 - 通貨/商品

0.52
( weak )

0.47
( neutral )

Aptinyx Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.950

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.950

FY	2021
収益:	$1.00M
総利益:	$0.00 (0.00 %)
EPS:	$0

FY	2020
収益:	$1.56M
総利益:	$1 564.00 (0.10 %)
EPS:	$-1.020

Financial Reports:

No articles found.

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.